Membership Matters STEVEN GROSSMAN 4/8/16 Membership Matters STEVEN GROSSMAN 4/8/16 Significant Upcoming Alliance Events Read More Analysis and Commentary STEVEN GROSSMAN 4/8/16 Analysis and Commentary STEVEN GROSSMAN 4/8/16 The Impracticalities of Uneconomics Read More Advocacy at a Glance STEVEN GROSSMAN 4/8/16 Advocacy at a Glance STEVEN GROSSMAN 4/8/16 Appropriations Subcommittee Allocations Coming Soon and more Read More Analysis and Commentary STEVEN GROSSMAN 4/1/16 Analysis and Commentary STEVEN GROSSMAN 4/1/16 It Costs Money to Wag the Tail of the Dog! Read More Advocacy at a Glance STEVEN GROSSMAN 4/1/16 Advocacy at a Glance STEVEN GROSSMAN 4/1/16 FDA’s Generics Performance Report and more Read More Analysis and Commentary STEVEN GROSSMAN 3/26/16 Analysis and Commentary STEVEN GROSSMAN 3/26/16 FDA-Related Legislation and Budgetary Implications Read More Advocacy at a Glance STEVEN GROSSMAN 3/26/16 Advocacy at a Glance STEVEN GROSSMAN 3/26/16 Introduction of FDA-Related Bills Continues Read More Analysis and Commentary STEVEN GROSSMAN 3/19/16 Analysis and Commentary STEVEN GROSSMAN 3/19/16 Alliance Overcomes Shutdown (of DC Metro System) Read More Advocacy at a Glance STEVEN GROSSMAN 3/19/16 Advocacy at a Glance STEVEN GROSSMAN 3/19/16 Alliance Capitol Hill Advocacy Day is a Success and more Read More Analysis and Commentary STEVEN GROSSMAN 3/12/16 Analysis and Commentary STEVEN GROSSMAN 3/12/16 Four Key Points for Hill Day 2016 Read More Advocacy at a Glance STEVEN GROSSMAN 3/12/16 Advocacy at a Glance STEVEN GROSSMAN 3/12/16 FDA to Apply Lean Management Tools to Handling of Combination Products and more Read More Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More Analysis and Commentary STEVEN GROSSMAN 2/27/16 Analysis and Commentary STEVEN GROSSMAN 2/27/16 "Everything is a high priority" for the FDA today Read More Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More Analysis and Commentary STEVEN GROSSMAN 2/19/16 Analysis and Commentary STEVEN GROSSMAN 2/19/16 Alliance Seeks $2.85 Billion for FDA for FY 17 Read More Advocacy at a Glance STEVEN GROSSMAN 2/19/16 Advocacy at a Glance STEVEN GROSSMAN 2/19/16 Alliance FY 17 “Ask” for FDA Funding Read More Analysis and Commentary STEVEN GROSSMAN 2/12/16 Analysis and Commentary STEVEN GROSSMAN 2/12/16 Of Smoke, Mirrors, and Advocacy Participation Read More Advocacy at a Glance STEVEN GROSSMAN 2/12/16 Advocacy at a Glance STEVEN GROSSMAN 2/12/16 President’s FY 17 Budget Request for FDA: Disappointing and Alarming and more Read More Uncategorized STEVEN GROSSMAN 2/10/16 Uncategorized STEVEN GROSSMAN 2/10/16 Alliance Alarmed and Disappointed by President's Budget Request for FY 17 Read More Newer Posts Older Posts
Membership Matters STEVEN GROSSMAN 4/8/16 Membership Matters STEVEN GROSSMAN 4/8/16 Significant Upcoming Alliance Events Read More
Analysis and Commentary STEVEN GROSSMAN 4/8/16 Analysis and Commentary STEVEN GROSSMAN 4/8/16 The Impracticalities of Uneconomics Read More
Advocacy at a Glance STEVEN GROSSMAN 4/8/16 Advocacy at a Glance STEVEN GROSSMAN 4/8/16 Appropriations Subcommittee Allocations Coming Soon and more Read More
Analysis and Commentary STEVEN GROSSMAN 4/1/16 Analysis and Commentary STEVEN GROSSMAN 4/1/16 It Costs Money to Wag the Tail of the Dog! Read More
Advocacy at a Glance STEVEN GROSSMAN 4/1/16 Advocacy at a Glance STEVEN GROSSMAN 4/1/16 FDA’s Generics Performance Report and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/26/16 Analysis and Commentary STEVEN GROSSMAN 3/26/16 FDA-Related Legislation and Budgetary Implications Read More
Advocacy at a Glance STEVEN GROSSMAN 3/26/16 Advocacy at a Glance STEVEN GROSSMAN 3/26/16 Introduction of FDA-Related Bills Continues Read More
Analysis and Commentary STEVEN GROSSMAN 3/19/16 Analysis and Commentary STEVEN GROSSMAN 3/19/16 Alliance Overcomes Shutdown (of DC Metro System) Read More
Advocacy at a Glance STEVEN GROSSMAN 3/19/16 Advocacy at a Glance STEVEN GROSSMAN 3/19/16 Alliance Capitol Hill Advocacy Day is a Success and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/12/16 Analysis and Commentary STEVEN GROSSMAN 3/12/16 Four Key Points for Hill Day 2016 Read More
Advocacy at a Glance STEVEN GROSSMAN 3/12/16 Advocacy at a Glance STEVEN GROSSMAN 3/12/16 FDA to Apply Lean Management Tools to Handling of Combination Products and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/4/16 Analysis and Commentary STEVEN GROSSMAN 3/4/16 Califf Debuts on Capitol Hill with Two Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 3/4/16 Advocacy at a Glance STEVEN GROSSMAN 3/4/16 National Biomedical Research Act Introduced Read More
Analysis and Commentary STEVEN GROSSMAN 2/27/16 Analysis and Commentary STEVEN GROSSMAN 2/27/16 "Everything is a high priority" for the FDA today Read More
Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Advocacy at a Glance STEVEN GROSSMAN 2/27/16 Details on FDA’s Request for FY 17 FSMA Appropriations and more Read More
Analysis and Commentary STEVEN GROSSMAN 2/19/16 Analysis and Commentary STEVEN GROSSMAN 2/19/16 Alliance Seeks $2.85 Billion for FDA for FY 17 Read More
Advocacy at a Glance STEVEN GROSSMAN 2/19/16 Advocacy at a Glance STEVEN GROSSMAN 2/19/16 Alliance FY 17 “Ask” for FDA Funding Read More
Analysis and Commentary STEVEN GROSSMAN 2/12/16 Analysis and Commentary STEVEN GROSSMAN 2/12/16 Of Smoke, Mirrors, and Advocacy Participation Read More
Advocacy at a Glance STEVEN GROSSMAN 2/12/16 Advocacy at a Glance STEVEN GROSSMAN 2/12/16 President’s FY 17 Budget Request for FDA: Disappointing and Alarming and more Read More
Uncategorized STEVEN GROSSMAN 2/10/16 Uncategorized STEVEN GROSSMAN 2/10/16 Alliance Alarmed and Disappointed by President's Budget Request for FY 17 Read More
